In terms of Regulation 33 read with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the Listing Regulations), Kabra Drugs has informed that the Unaudited Financial Results (Standalone) of the Company for the Quarter and Half-Year ended December 31, 2018 were approved by the Board of Directors of the Company at its meeting held.
The above information is a part of company’s filings submitted to BSE.
Trending Stocks
Recommended Articles
